Substance / Medication

Efinaconazole

Overview

Active Ingredient
efinaconazole
RxNorm CUI
1539753

Indications

Trichophyton rubrum Trichophyton mentagrophytes JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due toand.

Labeler: Bausch Health US LLCUpdated: 2025-07-01T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
0
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd:YAG laser for treatment of toenail onychomycosis.
Bonhert Krista, Dorizas Andrew, Sadick Neil S · J Cosmet Laser Ther · 2019
PMID: 30052090RCT
Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants.
Lipner Shari R, Gupta Aditya K, Vlahovic Tracey C et al. · J Drugs Dermatol · 2026
PMID: 41493257Trial
Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.
Eichenfield Lawrence F, Elewski Boni, Sugarman Jeffrey L et al. · J Am Acad Dermatol · 2021
PMID: 32622145Trial
Efinaconazole topical solution 10%: Formulation and efficacy assessment in the treatment of toenail onychomycosis.
Naeimifar Atefeh, Samadi Aniseh, Ahmad Nasrollahi Saman et al. · Mycoses · 2020
PMID: 32048351Trial
Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients.
Shofler David, Hamedani Elnaz, Seun Jonathan et al. · Clin Podiatr Med Surg · 2020
PMID: 32146992Trial
Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis.
Gupta Aditya K, Venkataraman Maanasa, Shear Neil H et al. · Dermatol Ther · 2020
PMID: 32418289Trial
Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
Eichenfield Lawrence F, Elewski Boni, Sugarman Jeffrey L et al. · J Drugs Dermatol · 2020
PMID: 33026753Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Efinaconazole (substance)
SNOMED CT
703880007
UMLS CUI
C3273754
RxNorm CUI
1539753
Labeler
Bausch Health US LLC

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.